{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:50Z","timestamp":1793145290823,"version":"4.5.0"},"reference-count":203,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ccell.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:42:45Z","timestamp":1780929765000},"page":"1126-1146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antibody-drug conjugates in precision oncology"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"Mosele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.05.004_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/nyas.12499","article-title":"Antibody-drug conjugates: an emerging modality for the treatment of cancer","volume":"1321","author":"Leal","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ccell.2026.05.004_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib3","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib5","series-title":"Cancer Drugs (Antibody Drug Conjugates): An FDA Perspective","year":"2024"},{"key":"10.1016\/j.ccell.2026.05.004_bib6","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab Vedotin: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ccell.2026.05.004_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor\u2013Positive Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib9","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ccell.2026.05.004_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ccell.2026.05.004_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","volume":"59","author":"Bareford","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ccell.2026.05.004_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody\u2212Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ccell.2026.05.004_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ccell.2026.05.004_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2026.05.004_bib15","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/annonc\/mdr484","article-title":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines","volume":"23","author":"Collins","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib16","doi-asserted-by":"crossref","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib18","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","article-title":"Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1\/2-wild-type Triple-Negative Breast Cancer","volume":"23","author":"Cardillo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ccell.2026.05.004_bib20","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","article-title":"The role of UGT1A1\u221728 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Toffoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.004_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","article-title":"Genomics to select treatment for patients with metastatic breast cancer","volume":"610","author":"Andre","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.004_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib24","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib25","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.ccell.2026.05.004_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib29","series-title":"FDA Approves Enfortumab Vedotin-Ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer","year":"2024"},{"key":"10.1016\/j.ccell.2026.05.004_bib31","article-title":"Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study","volume":"2","author":"Giordano","year":"2025","journal-title":"JCO Oncol. Adv"},{"key":"10.1016\/j.ccell.2026.05.004_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115603","article-title":"Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study","volume":"227","author":"Muro","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2026.05.004_bib33","article-title":"Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study","author":"Vulsteke","year":"2025","journal-title":"ESMO Congr. 2025 LBA2"},{"key":"10.1016\/j.ccell.2026.05.004_bib34","unstructured":"Inc, A.P. PADCEVTM Plus Keytruda\u00ae Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. https:\/\/www.prnewswire.com\/news-releases\/padcev-plus-keytruda-significantly-improves-survival-for-patients-with-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility-302644184.html."},{"key":"10.1016\/j.ccell.2026.05.004_bib35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrclinonc.2012.36","article-title":"HER2\u2014a good addiction","volume":"9","author":"Carey","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib37","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib38","first-page":"57","article-title":"HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series","volume":"32","author":"Grabsch","year":"2010","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib40","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1538-7445.AM2024-1366","article-title":"Abstract 1366: Dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models","volume":"84","author":"Jenkins","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib41","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1158\/1538-7445.AM2023-2944","article-title":"Abstract 2944: Trastuzumab-deruxtecan (T-Dxd) induces superior macrophage\/DC activation, antigen-presentation and anti-tumor adaptive immune responses, which can be augmented by CD47\/SIRPA blockade","volume":"83","author":"Tsao","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib43","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","article-title":"Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial","volume":"31","author":"Pistilli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib45","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib46","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ccell.2026.05.004_bib47","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","article-title":"OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial","volume":"19","author":"Besse","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib48","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib49","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib50","first-page":"25","article-title":"Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer","volume":"16","author":"Rocha Lima","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ccell.2026.05.004_bib51","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/molecules25184136","article-title":"The Potential Role of Cathepsin K in Non-Small Cell Lung Cancer","volume":"25","author":"Yang","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ccell.2026.05.004_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.annonc.a010484","article-title":"Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer","volume":"7","author":"Nooter","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab Tirumotecan in EGFR-TKI\u2013Resistant, EGFR-Mutated Advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib54","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib55","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib56","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.cellsig.2015.03.017","article-title":"Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17","volume":"27","author":"Wanger","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ccell.2026.05.004_bib57","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib58","first-page":"171","article-title":"Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer","author":"Planchard","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.004_bib59","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1200\/JCO-25-00716","article-title":"Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2\u2013Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial","volume":"44","author":"Liu","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1435485","article-title":"Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study","volume":"14","author":"Qu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib61","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib62","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib63","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein\u2013Overexpressing Advanced Nonsquamous EGFR-Wildtype Non\u2013Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib64","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody\u2013drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccell.2026.05.004_bib65","first-page":"2100","article-title":"A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. Clin. Cancer Res. Off. J. Am. Assoc","volume":"27","author":"Cazes","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ccell.2026.05.004_bib67","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1158\/1078-0432.CCR-25-2333","article-title":"Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate","volume":"31","author":"Ozawa","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117305","article-title":"Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition","volume":"286","author":"Li","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ccell.2026.05.004_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149214","article-title":"An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment","volume":"688","author":"Chang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ccell.2026.05.004_bib70","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1021\/acs.jmedchem.1c01920","article-title":"Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ccell.2026.05.004_bib71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2019.02.006","article-title":"Anti-tumor activity of antibody drug conjugate targeting aspartate-\u03b2-hydroxylase in pancreatic ductal adenocarcinoma","volume":"449","author":"Nagaoka","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ccell.2026.05.004_bib72","first-page":"158","article-title":"An antibody-drug conjugate targeting soluble and membrane-bound TGF\u03b1 is effective against pancreatic tumors","volume":"44","author":"Romero-P\u00e9rez","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.ccell.2026.05.004_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117798","article-title":"Triptolide-based cleavable antibody-drug conjugates for pancreatic cancer","volume":"295","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ccell.2026.05.004_bib74","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2025.43.16_suppl.4017","article-title":"Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2842","article-title":"2225P Tissue factor (TF) antibody-drug conjugate (ADC) MRG004A in patients (pts) with advanced pancreatic cancer (PC): Updated results from a phase I study","volume":"36","author":"Ren","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib76","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2025.43.16_suppl.4018","article-title":"Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study","volume":"43","author":"Lentz","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2831","article-title":"2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)","volume":"36","author":"Harding","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib78","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111792","article-title":"Advancing Antibody\u2013Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers","volume":"17","author":"Yajaman","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ccell.2026.05.004_bib80","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib81","doi-asserted-by":"crossref","first-page":"GS1-09","DOI":"10.1158\/1557-3265.SABCS25-GS1-09","article-title":"Abstract GS1-09: Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+\/HER2\u2212 (IHC 0, 1+, 2+\/ISH\u2212) metastatic breast cancer: Primary results from ASCENT-07","volume":"32","author":"Jhaveri","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib82","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2026.05.004_bib83","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.ccell.2026.05.004_bib84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Lewis Phillips","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ccell.2026.05.004_bib85","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1158\/1535-7163.MCT-18-0329","article-title":"Unraveling the Interaction between Carboxylesterase 1c and the Antibody\u2013Drug Conjugate SYD985: Improved Translational PK\/PD by Using Ces1c Knockout Mice","volume":"17","author":"Ubink","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib86","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/00498254.2024.2345849","article-title":"Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species","volume":"54","author":"Yip","year":"2024","journal-title":"Xenobiotica."},{"key":"10.1016\/j.ccell.2026.05.004_bib87","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s11095-015-1626-1","article-title":"Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development","volume":"32","author":"Singh","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib88","article-title":"Re-Evaluating Antibody\u2013Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation","volume":"0","author":"Colombo","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib89","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432516","article-title":"New Treatment Options for Patients With Oncogene-Addicted Non\u2013Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors","volume":"44","author":"Saw","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.ccell.2026.05.004_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib91","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib92","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.004_bib94","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.004_bib95","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor Cells Chronically Treated with a Trastuzumab\u2013Maytansinoid Antibody\u2013Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib96","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib97","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1158\/1538-7445.AM2024-5857","article-title":"Abstract 5857: Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained","volume":"84","author":"Nilsson","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib98","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P2-09-03","article-title":"Abstract P2-09-03: Quantification of HER2 expression and spatial biology using computational pathology: A cross-assay validation study in breast cancer","volume":"83","author":"Drago","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib99","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","article-title":"Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer","volume":"102","author":"Moutafi","year":"2022","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ccell.2026.05.004_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61957-9","article-title":"HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer","volume":"14","author":"Kapil","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ccell.2026.05.004_bib101","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib102","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-cancerbio-030617-050224","article-title":"Lineage Plasticity in Cancer Progression and Treatment","volume":"2","author":"Le Magnen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.ccell.2026.05.004_bib103","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib104","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2026.05.004_bib105","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib107","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.004_bib109","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.01.007","article-title":"Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs","author":"Nilsson","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib111","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate","volume":"21","author":"Cabaud","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib112","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1158\/1538-7445.AM2025-7148","article-title":"Abstract 7148: Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02)","volume":"85","author":"Siena","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-025-00868-y","article-title":"Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling","volume":"12","author":"Sledge","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ccell.2026.05.004_bib114","first-page":"996","article-title":"Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers. Cancer Sci","volume":"117","author":"Murase","year":"2026","journal-title":"n\/a"},{"key":"10.1016\/j.ccell.2026.05.004_bib115","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO-25-01235","article-title":"Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates","volume":"43","author":"Vogel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib116","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s43018-025-00969-4","article-title":"p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy","volume":"6","author":"Hu","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.05.004_bib117","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib118","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: A dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.004_bib119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib120","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib121","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.004_bib122","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib123","first-page":"960","article-title":"Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry","volume":"10","author":"He","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.ccell.2026.05.004_bib124","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.3390\/app11209437","article-title":"Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method","volume":"11","author":"Park","year":"2021","journal-title":"Appl. Sci."},{"key":"10.1016\/j.ccell.2026.05.004_bib125","first-page":"851","article-title":"Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed\/refractory multiple myeloma. CPT Pharmacomet","volume":"10","author":"Rathi","year":"2021","journal-title":"Syst. Pharmacol."},{"key":"10.1016\/j.ccell.2026.05.004_bib126","first-page":"157","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib127","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1078-0432.CCR-21-3261","article-title":"Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study","volume":"28","author":"Herrera","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib128","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib129","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500305","article-title":"Advanced Antibody\u2013Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies","volume":"26","author":"Matsuda","year":"2025","journal-title":"Chembiochem."},{"key":"10.1016\/j.ccell.2026.05.004_bib130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","article-title":"Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib131","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2026.05.004_bib132","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1158\/1538-7445.AM2025-6369","article-title":"Abstract 6369: Perivascular niche-resident alveolar macrophages confer interstitial pneumonitis related to trastuzumab deruxtecan","volume":"85","author":"Wei","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib133","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-16-0710","article-title":"Inhibition of Megakaryocyte Differentiation by Antibody\u2013Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib134","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ccell.2026.05.004_bib136","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating Fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ccell.2026.05.004_bib137","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/pharmaceutics18030354","article-title":"Applications of Pharmacometrics in Antibody\u2013Drug Conjugate Development","volume":"18","author":"Cheng","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ccell.2026.05.004_bib138","series-title":"Project Optimus","article-title":"of the","author":"Commissioner","year":"2024"},{"key":"10.1016\/j.ccell.2026.05.004_bib139","author":"Research"},{"key":"10.1016\/j.ccell.2026.05.004_bib140","unstructured":"https:\/\/www.cde.org.cn\/zdyz\/downloadAtt?idCODE=81a950a7446beef99b90435802279543. - Buscar con Google https:\/\/www.google.com\/search?q=(https%3A%2F%2Fwww.cde.org.cn%2Fzdyz%2FdownloadAtt%3FidCODE%3D81a950a7446beef99b90435802279543).&rlz=1C1CHBD_frFR1069FR1069&oq=(https%3A%2F%2Fwww.cde.org.cn%2Fzdyz%2FdownloadAtt%3FidCODE%3D81a950a7446beef99b90435802279543).&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBBzUzNGowajGoAgCwAgA&sourceid=chrome&ie=UTF-8."},{"key":"10.1016\/j.ccell.2026.05.004_bib141","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ccell.2026.05.004_bib142","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ccell.2026.05.004_bib143","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2005.01.016","article-title":"What Is Targeted Therapy?","volume":"23","author":"Sledge","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib144","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib145","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib146","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody\u2013Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib147","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib148","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/1078-0432.CCR-24-1948","article-title":"Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib149","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib150","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib151","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib152","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I\/II Trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib153","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib154","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/1538-7445.AM2023-2932","article-title":"Abstract 2932: Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1\/PD-L1 inhibitors in TROP2-expressing tumors in mice","volume":"83","author":"Okajima","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib155","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib156","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","article-title":"Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer","volume":"43","author":"Ma","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.004_bib157","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib158","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib159","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1038\/s41591-025-03711-w","article-title":"Cancer treatment paradigms in the precision medicine era","volume":"31","author":"Subbiah","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib160","doi-asserted-by":"crossref","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib161","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1016\/j.annonc.2025.08.978","article-title":"555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Final results from the phase Ib\/II BEGONIA study","volume":"36","author":"Schmid","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104164","article-title":"8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab \u00b1 carboplatin in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4)","volume":"10","author":"Cuppens","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ccell.2026.05.004_bib163","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jtho.2023.09.043","article-title":"OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab \u00b1 Carboplatin in Advanced\/mNSCLC: Initial Results from Phase 1b TROPION-Lung04","volume":"18","author":"Papadopoulos","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib164","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.annonc.2025.11.005","article-title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","volume":"37","author":"Hurvitz","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib165","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1158\/2767-9764.CRC-23-0302","article-title":"HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer","volume":"3","author":"Olson","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ccell.2026.05.004_bib166","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.004_bib167","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ccell.2026.05.004_bib168","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib169","doi-asserted-by":"crossref","first-page":"CT267","DOI":"10.1158\/1538-7445.AM2025-CT267","article-title":"Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors","volume":"85","author":"Ulahannan","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.004_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.1508","article-title":"939P Phase I, dose-escalation study evaluating safety & efficacy of trastuzumab deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, ceralasertib) in advanced solid tumors with HER2 expression (DASH)","volume":"36","author":"Raghav","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib171","doi-asserted-by":"crossref","first-page":"S1153","DOI":"10.1016\/j.annonc.2024.08.2080","article-title":"1994P Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in \u2265 second line in metastatic urothelial carcinoma (mUC)","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib172","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.05.004_bib173","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ccell.2026.05.004_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-024-00784-7","article-title":"Assessment of targets of antibody drug conjugates in SCLC","volume":"9","author":"Ajay","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib175","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib176","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib177","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2025.43.16_suppl.3009","article-title":"Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate","volume":"43","author":"Hamilton","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib178","unstructured":"Recent Advances in ADCs NJ Bio Inc. https:\/\/njbio.com\/antibody-drug-conjugates\/."},{"key":"10.1016\/j.ccell.2026.05.004_bib179","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.18632\/oncotarget.13907","article-title":"The role of tumor microenvironment in therapeutic resistance","volume":"8","author":"Son","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccell.2026.05.004_bib180","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ccell.2026.05.004_bib181","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ccell.2026.05.004_bib182","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ddtec.2018.09.003","article-title":"Bispecifics and antibody-drug conjugates: A positive synergy","volume":"30","author":"Maruani","year":"2018","journal-title":"Drug Discov. Today. Technol."},{"key":"10.1016\/j.ccell.2026.05.004_bib183","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.004_bib184","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib185","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1038\/s41591-025-03792-7","article-title":"A bispecific antibody\u2013drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104874","article-title":"302MO Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic breast cancer (BC)","volume":"10","author":"Zhang","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ccell.2026.05.004_bib187","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2025.43.16_suppl.3002","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC)","volume":"43","author":"Huang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib188","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib7020016","article-title":"Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.ccell.2026.05.004_bib189","unstructured":"Biologics, I. Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies. https:\/\/www.prnewswire.com\/news-releases\/innovent-announces-first-patient-dosed-in-phase-1-study-of-ibi3020-global-first-in-class-dual-payload-ceacam5-adc--in-patients-with-advanced-malignancies-302441146.html."},{"key":"10.1016\/j.ccell.2026.05.004_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.1073","article-title":"653eTiP Translational study and first-in-human (FIH) study design of KH815, a novel dual-payload TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"36","author":"Ma","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib191","article-title":"Hutchmed begins Phase I HMPL-A251 clinical development programme","author":"Gullapalli","year":"2025","journal-title":"Clin. Trials Arena"},{"key":"10.1016\/j.ccell.2026.05.004_bib192","unstructured":"Ltd, A.T.P. Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOTTM Technology. https:\/\/www.prnewswire.com\/news-releases\/axcynsis-therapeutics-receives-fda-clearance-for-ind-application-of-at03-65-a-differentiated-cldn6-targeting-adc-powered-by-axcyndot-technology-302350114.html."},{"key":"10.1016\/j.ccell.2026.05.004_bib193","unstructured":"Delving into the Latest Updates on GFS784 with Synapse https:\/\/synapse.patsnap.com\/drug\/582859b74141466f885110dea4531bbf."},{"key":"10.1016\/j.ccell.2026.05.004_bib194","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib196","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib197","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib198","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib199","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2025.43.16_suppl.511","article-title":"A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial","volume":"43","author":"Abelman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib200","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/s41591-024-03266-2","article-title":"Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Khoury","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib201","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.annonc.2025.02.011","article-title":"Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial","volume":"36","author":"Li","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.004_bib202","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.004_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104424","article-title":"Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors: A cross-sectional study","volume":"80","author":"Gehr","year":"2025","journal-title":"The Breast"},{"key":"10.1016\/j.ccell.2026.05.004_bib204","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metab. Dispos."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826002497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826002497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:27:14Z","timestamp":1781296034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826002497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":203,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1535610826002497"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.05.004","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates in precision oncology","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}